Tempus AI Inc. stocks have been trading up by 12.58 percent, driven by strong AI healthcare adoption and investor optimism
Click Here for a Millionaire's POV on Trading TEM
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Tempus AI is buying Personalis in an all‑stock deal worth about $1.5B, or $16.25 per PSNL share, implying roughly 15.5x estimated 2027 EV/sales.
- The Personalis acquisition is mainly stock‑funded, with Tempus able to pay up to 50% in cash, and is expected to close around late 2026 to early 2027 pending approvals.
- Shares of TEM slid between roughly 4% and 6.9% after the deal news, signaling market concern over valuation, dilution, and execution while the broader healthcare tape stayed flat‑to‑soft.
- Needham called the multiple rich versus small‑ and mid‑cap growth peers but argued it is supported by Personalis’ NeXT Personal MRD growth prospects and recent Medicare reimbursement traction.
- A shareholder‑rights firm is reviewing whether Tempus AI’s prior stake and partnership with Personalis created conflicts that hurt PSNL holders on the $16.25 per‑share takeout.
Weekly Update Aug 03 – Aug 07, 2026: On Saturday, August 08, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 12.58%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Tempus AI (TEM) sits in a premium-growth, early-scale position within healthcare AI and precision oncology, but fundamentals remain loss-making and capital intensive. Gross margin at 73.5% is excellent and consistent with a data/diagnostics platform, yet EBIT margin of -14.4% and ROE of roughly -67% highlight an equity-heavy, low-return model today. Cash of ~$816M, current ratio 3.3, and debt-to-equity 0.61 provide ample runway, but free cash flow is negative and share-based comp is materially inflating reported profitability.
Technically, TEM’s tape shows aggressive buying interest after the Personalis deal overhang: the stock jumped from the mid‑$46s to a $52 handle, breaking above a short-term consolidation band near $46–47. Weekly structure is a nascent uptrend with higher highs and higher lows, confirmed by strong volume on the $52 breakout. The key actionable level is ~$47: above it the long bias is intact, while a close below $47 would signal failed breakout and a likely retest of the low‑$40s.
More Breaking News
- HL Stock Holds Gains As Cash Flow, Silver Output Jump
- NAMI Stock Spurs Volatility As Traders Target Breakout
- DSY Stock Whipsaws As Traders Zero In On Key Levels
- ONDS Stock Pops As U.S. Defense Orders Power New Uptrend
The Personalis acquisition is strategically sound, vaulting TEM into the high-growth MRD oncology market (estimated ~$20B) and deepening its integrated data-diagnostics moat versus healthcare and healthcare providers & services peers that lack comparable AI-ready datasets. Near term, stock pressure reflects deal size (EV ~$1.5B, rich multiple) and integration risk, but balance sheet capacity and limited antitrust risk are adequate. I view risk/reward as favorable with support at $47, resistance near $55–57, and a 12–18 month upside target of $65.
Quick Financial Overview
Tempus AI Inc. (TEM) is leaning hard into its data‑driven oncology strategy with the Personalis move. The company is already positioned as a major AI‑and‑healthcare player, running genomic diagnostics on a large patient base and licensing data back to pharma. Revenue of about $1.27B and a gross margin of 73.5% show strong top‑line scale and high‑value services, but the negative EBIT margin of -14.4% and profit margin of -17.77% highlight an aggressive spend profile.
From a balance‑sheet angle, Tempus AI Inc. shows solid liquidity with a current ratio of 3.3, cash and short‑term investments above $800M, and total debt to equity at 0.61. Enterprise value sits near $8.85B, with a price‑to‑sales of 5.81 and price‑to‑book near 18.7, which are high multiples that bake in strong growth expectations. Returns on equity and assets are sharply negative, reflecting ongoing losses and heavy reinvestment into the platform.
On the tape, TEM has been volatile around the Personalis news. After trading around the mid‑$40s, the weekly data show a push to the low‑$50s, with an intraday spike from roughly $47.55 to $52.40 and a close near $52.05 on the breakout day. That kind of wide intraday range tells traders there is active price discovery and strong two‑sided interest, with the $46‑$47 zone acting as recent support and the low‑$50s emerging as a short‑term resistance band.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.